Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and tolerability of AB598 when
taken alone, and in combination with zimberelimab and standard chemotherapy in participants
with advanced malignancies.